Braveheart Bio Prices Upsized IPO at $18 Per Share

Key Facts

In a move reflecting growing confidence in the biotechnology sector, Braveheart Bio announced the pricing of its initial public offering at $18.00 per share. The company upsized the offering to 21,250,000 shares of common stock, signaling robust investor appetite. Shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol BRVE on August 6, 2026.

The company aims to raise gross proceeds of approximately $382.5 million before expenses to fund the development of therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases. According to the reported data, Braveheart Bio has granted underwriters a 30-day option to purchase up to an additional 3.18 million shares at the IPO price, which could further increase the total capital raised.

Official trading for BRVE is scheduled to commence on August 6, 2026, with markets watching for price stability above the initial offering level. As current price data is unavailable prior to the listing, focus will shift to broader healthcare sector performance, especially as the upcoming economic calendar shows no immediate catalysts directly impacting this specific debut.